Quantcast
Home > Quotes > SUPN

Supernus Pharmaceuticals, Inc. Common Stock (SUPN) Quote & Summary Data

SUPN 
$43.96
*  
0.85
1.97%
Get SUPN Alerts
*Delayed - data as of Nov. 16, 2018  -  Find a broker to begin trading SUPN now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 44.03 / $ 42.14
Share Volume
437,566
50 Day Avg. Daily Volume
574,325
Previous Close
$ 43.11
52 Week High / Low
$ 61.25 / $ 34.90
Market Cap
2,297,218,291
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
437,566
50 Day Avg. Daily Volume:
574,325

P/E Ratio

P/E Ratio:
23.89
Forward P/E (1y):
23.05
Earnings Per Share (EPS):
$ 1.84

Trading Range

The current last sale of $43.96 is 25.96% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 44.03 $ 61.25
 Low: $ 42.14 $ 34.90

Company Description (as filed with the SEC)

We are a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Oxtellar XR and Trokendi XR are the first once-daily extended release oxcarbazepine and topiramate products indicated for the treatment of epilepsy in the U.S. market. In April 2017, we launched Trokendi XR as a new product for prophylaxis of migraine headache in adults and adolescents. In addition, we are developing multiple product candidates in psychiatry to address significant unmet medical needs and market opportunities. We are developing SPN-810 (molindone hydrochloride) initially to treat impulsive aggression (IA) in children and adolescents who have attention deficit hyperactivity disorder (ADHD). We plan to subsequently develop SPN-810 for the treatment of IA in other CNS diseases, such as autism, post traumatic stress disorder (PTSD), bipolar disorder, schizophrenia, and some forms of dementia.  ... More ...  


Risk Grade

Where does SUPN fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 42.84
Open Date:
Nov. 16, 2018
Close Price:
$ 43.11
Close Date:
Nov. 16, 2018

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x